QuidelOrtho Corporation (NASDAQ: QDEL) will release its fourth‑quarter and full‑year 2025 financial results on February 11, 2026, after the market close, and will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) to discuss the data. The company will post presentation materials and a replay of the call on its Investor Relations website.
In the third quarter of 2025, QuidelOrtho generated $700 million in revenue, a 4% decline year‑over‑year, largely due to lower COVID‑19 and donor‑screening sales. Adjusted diluted earnings per share fell to $0.80 from $0.85 in the same period last year, while adjusted EBITDA margin expanded to 25% from 22% as cost‑saving initiatives took effect. For the full year 2024, the company reported revenue between $2.75 billion and $2.80 billion and adjusted EBITDA of $530 million to $550 million, setting the stage for its 2025 outlook.
The mixed performance reflects a shift in the company’s revenue mix. While legacy COVID‑19 and donor‑screening segments contracted, non‑respiratory and laboratory businesses grew 5% and 4% in constant currency, respectively. Cost‑control measures, including a focused restructuring of the donor‑screening portfolio and operational efficiencies across the labs segment, have lifted margins and offset the decline in legacy revenue streams.
President and CEO Brian J. Blaser highlighted the company’s momentum, noting that the underlying business is gaining traction through a recurring‑revenue model. He emphasized the importance of cost discipline, leadership realignment, and the pursuit of high‑growth, high‑margin opportunities, framing the upcoming earnings as a testament to the company’s execution of its strategic priorities.
Analysts had projected earnings per share of $0.51 and revenue of $667.45 million for Q3 2025; the company’s actual results beat those estimates, underscoring the effectiveness of its cost‑saving program. For 2025, QuidelOrtho has guided revenue of $2.60 billion to $2.81 billion and adjusted EBITDA of $575 million to $615 million, maintaining an adjusted EBITDA margin of 22%. Guidance for 2026 has not yet been disclosed, leaving investors to assess the company’s trajectory based on the 2025 outlook and the ongoing shift in its revenue mix.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.